News

Keyword Search

Year

May 30, 2023

CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

SEATTLE , May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of

May 10, 2023

Sobi to Acquire CTI BioPharma

Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE , May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted

May 02, 2023

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , May 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of

May 01, 2023

CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on

May 01, 2023

CTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

– Data presentation on spleen volume reduction in patients with myelofibrosis also accepted for poster discussion – SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted

Apr 12, 2023

CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023

SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will participate in two

Apr 10, 2023

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , April 10, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee

Mar 20, 2023

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , March 20, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee

Mar 06, 2023

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of

Mar 06, 2023

CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results

– Growing physician awareness and usage of VONJO ® (pacritinib) drove quarterly double-digit revenue growth – – VONJO ® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – – ASH 2022

Pagination

Current page 1
Page 2
Next page
Last page

Investors

News

News

Keyword Search

–

–

–

–